Triastek Revenue, Valuation, Funding & Investors

LightForce Orthodontics makes a fully personalized, 3D-printed braces system that uses AI and digital workflows to design custom brackets for each patient's anatomy. Orthodontists use the platform for treatment planning, from intraoral scans through final prescriptions, aiming to shorten treatment timelines and reduce the number of patient visits compared with standard orthodontics. The company manufactures its brackets in the United States, including at a facility in Wilmington, Massachusetts.

Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.

3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.

Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

ReCode Therapeutics is a Menlo Park, California-headquartered clinical-stage genetic medicines company developing mRNA and gene-edited therapies. Its SORT LNP platform enables extrahepatic delivery to lungs and other organs for diseases like primary ciliary dyskinesia and cystic fibrosis. ReCode advances RCT2100 into Phase II trials and partners with CRISPR pioneers for targeted corrections.

SWISSto12 is a Lausanne-headquartered manufacturer of 3D-printed millimeter-wave components like waveguides and antennas. Spun off from EPFL in 2017, it produces lightweight aluminum structures for satellite communications, 5G base stations, and radar systems. SWISSto12 supplies Thales and Airbus with additive-manufactured parts reducing weight by 40 percent compared to traditional machining.

Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases. The firm advances AAV-based therapies for X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis using its spreading capsid AAV.SPR platform. Headquartered in Raleigh, North Carolina, Atsena Therapeutics conducts trials targeting genetic mutations causing blindness.

Seurat Technologies is a Boston-headquartered developer of Area Printing, a high-speed 3D metal additive manufacturing process originating from Lawrence Livermore National Laboratory. Founded in 2019, it holds over 130 patents and targets mass production of metal parts for aerospace and automotive industries. Seurat's technology achieves micron-level resolution at rates competing with casting, reducing carbon emissions in manufacturing.

Vanqua Bio is a Cambridge, Massachusetts-headquartered biotech firm developing therapies for neurodegenerative diseases like Parkinson's and ALS using a platform that screens human genetics and patient-derived neurons targeting lysosomal storage disorders and innate immune activation pathways.

Mighty Buildings is a San Francisco-headquartered construction technology firm using 3D printing and robotics to manufacture modular homes. The company extrudes Light Stone Material panels onsite, assembling structures in days with superior insulation to concrete. Mighty Buildings targets single-family and ADU homes compliant with California building codes. Founded in 2017, it operates a factory in Oakland producing units for Bay Area developers.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Casma Therapeutics is a biotechnology company engineering small molecules to modulate autophagy for treating neurodegenerative and muscle diseases. Cambridge, Massachusetts-headquartered, it targets lysosomal storage disorders and inflammation through selective TFEB and ULK1 activators. The firm advanced its lead candidate into preclinical studies for Parkinson's disease models.

Pulmocide is a clinical-stage biopharmaceutical company that develops inhaled antifungal drugs targeting severe respiratory infections such as invasive pulmonary aspergillosis. Its lead product candidate, PC945, enters the lungs directly to achieve high local concentrations while minimizing systemic exposure, currently advancing through Phase 2b trials in Europe and the US. The Cambridge, UK-headquartered firm, established in 2015, collaborates with the Cystic Fibrosis Trust and has raised over $50 million in funding from investors including the Wellcome Trust and Innovate UK. Pulmocide's pipeline also includes PC656 for influenza-associated aspergillosis, addressing unmet needs in immunocompromised patients.

Chabiotech Co Ltd is engaged in the manufacturing of biological products.